Microbot Medical (MBOT)

Its lead platform is LIBERTY, an endovascular robotic surgical system designed for use in a range of vascular interventions. Unlike many capital-intensive robotic platforms, LIBERTY is designed as a fully disposable system, which is intended to simplify setup, reduce the need for large fixed installations, and address concerns related to sterilization and cross-contamination. The system is built to let physicians remotely manipulate endovascular tools, potentially helping limit radiation exposure from fluoroscopy and improving ergonomics during lengthy procedures.

Microbot Medical operates as a development-stage company, with its business focused on research, design, testing, and the regulatory pathway for its robotic devices. It reports a single operating segment: the development of robotic devices for endoluminal surgery. Its commercial opportunity depends on clinical performance, regulatory approvals, physician adoption, hospital purchasing decisions, and the ability to demonstrate advantages over existing manual catheter techniques.

For investors, MBOT represents a highly specialized medical technology exposure. The company is not a diversified healthcare manufacturer; its value is closely tied to the progress of LIBERTY and related robotic systems in the competitive market for minimally invasive and image-guided procedures.